Type 2 Diabetes Mellitus and Heart Failure

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Pharmacotherapy

• Publication date

  2008-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1592/phco.28.2.170PMID 18225964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Standards of medical care in diabetes--2007.

  2009cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes

  2007cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes

  2007cited by this paper
• Effect of ramipril on the incidence of diabetes.

  2006cited by this paper
• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

  2006cited by this paper
• Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure

  2006cited by this paper
• The DREAM trial – Authors' reply

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006influential reference
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  2006cited by this paper
• Standards of Medical Care in Diabetes: Response to Power

  2006cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2006cited by this paper
• The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy

  2006cited by this paper
• Predictors of mortality and morbidity in patients with chronic heart failure.

  2006cited by this paper
• Evaluation and management of patients with acute decompensated heart failure.

  2006cited by this paper
• Diabetic cardiomyopathy.

  2006cited by this paper
• Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

  2005cited by this paper
• Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2005cited by this paper
• Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure

  2005cited by this paper
• Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.

  2005cited by this paper
• Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.

  2005influential reference
• Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure.

  2005cited by this paper
• Disproportionate increase in prevalence of diabetes among patients with congestive heart failure due to systolic dysfunction.

  2005cited by this paper
• Clinical factors associated with hyperkalemia in patients with congestive heart failure.

  2005cited by this paper
• Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes: Results of the HOPE Study Extension

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005influential reference
• Clinical factors associated with hyperkalemia in patients with congestive heart failure 1

  2005cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study

  2005influential reference
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004cited by this paper
• Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

  2004cited by this paper
• The association of fasting glucose levels with congestive heart failure in diabetic adults > or =65 years: the Cardiovascular Health Study.

  2004cited by this paper
• The incidence of congestive heart failure in type 2 diabetes: an update.

  2004cited by this paper
• Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure.

  2004cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

  2003cited by this paper
• Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

  2003cited by this paper
• Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.

  2003influential reference
• Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

  2003cited by this paper
• Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

  2003cited by this paper
• Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

  2003cited by this paper
• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.

  2003cited by this paper
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• Heart failure: the frequent, forgotten, and often fatal complication of diabetes.

  2003cited by this paper
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

  2003cited by this paper
• The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.

  2003cited by this paper
• Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction

  2003cited by this paper
• Metformin and thiazolidinedione use in Medicare patients with heart failure.

  2003cited by this paper
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2002cited by this paper
• Frequency of inappropriate metformin prescriptions.

  2002cited by this paper
• ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary

  2002cited by this paper
• When are medication side effects due to the nocebo phenomenon

  2002cited by this paper
• Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

  2002cited by this paper
• Nonhypoglycemic Effects of Thiazolidinediones

  2001cited by this paper
• Contraindications to metformin therapy in patients with Type 2 diabetes—a population‐based study of adherence to prescribing guidelines

  2001cited by this paper
• Nonhypoglycemic effects of thiazolidinediones.

  2001cited by this paper
• Glycemic Control and Heart Failure Among Adult Patients With Diabetes

  2001cited by this paper
• Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors.

  2001cited by this paper
• Ramipril and the development of diabetes.

  2001cited by this paper
• Effect of carvedilol on survival in severe chronic heart failure.

  2001cited by this paper
• Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.

  2001cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure

  2001cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.

  1999cited by this paper
• Diabetes and acute myocardial infarction: the role of insulin therapy.

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Diabetes and cardiovascular disease.

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Diabetic cardiomyopathy

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

  1998cited by this paper
• Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.

  1996cited by this paper
• Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

  1996cited by this paper
• Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

  1995cited by this paper
• The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction

  1995cited by this paper
• A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.

  1995cited by this paper
• The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.

  1995cited by this paper
• Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure

  1995cited by this paper
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

  1992cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1988cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper
• Diabetes and cardiovascular disease. The Framingham study.

  1979cited by this paper
• Role of diabetes in congestive heart failure: the Framingham study.

  1974cited by this paper
• A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.

  1970cited by this paper

• Effect of tofogliflozin on cardiac sympathetic nerve activity in type 2 diabetes mellitus patients with heart failure (TARGET-HF): rationale and design of the single-arm intervention trial

  2025cites this paper
• Outcomes in diabetic vs nondiabetic patients requiring cardiac resynchronization therapy for heart failure: A meta-analysis

  2025cites this paper
• Risk factor structure of heart failure in patients with cancer after treatment with anticancer agents’ assessment by big data from a Japanese electronic health record

  2023cites this paper
• Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway

  2022cites this paper
• BIOMARKER AND ECHOCARDIOGRAPHIC CHARACTERISTICS OF HEART FAILURE IN PATIENTS HAVING ACUTE MYOCARDIAL INFARCTION COMBINED WITH DIABETES MELLITUS OF TYPE 2.

  2022cites this paper
• The Elderly Subjects and Their Troubles

  2021cites this paper
• Enhancing antioxidant and anti-hyperglycaemic functions of gingko biloba L. seeds using thermal detoxification

  2021cites this paper
• Sex Differences of the Diabetic Heart

  2021cites this paper
• Butea monosperma flower extract partially reduces high-fat diet induced obesity in experimental rats

  2020cites this paper
• Review on Plants for Management of Diabetes in India: An Ethno- Botanical and Pharmacological Perspective

  2020cites this paper
• Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps: JACC State-of-the-Art Review.

  2020cites this paper
• Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts

  2019cites this paper
• Re-evaluating the causes and consequences of non-resolving inflammation in chronic cardiovascular disease

  2019cites this paper
• Zebrafish: A Model for Marine Peptide Based Drug Screening

  2019cites this paper
• JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure　- Digest Version.

  2019cites this paper
• Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabétique

  2019cites this paper
• Japan Heart Failure Model　― Derivation and Accuracy of Survival Prediction in Japanese Heart Failure Patients ―

  2018cites this paper
• Type-2 diabetic aldehyde dehydrogenase 2 mutant mice (ALDH 2*2) exhibiting heart failure with preserved ejection fraction phenotype can be determined by exercise stress echocardiography

  2018cites this paper
• Metformin in heart failure patients

  2017cites this paper
• Influence of diabetes on cardiac resynchronization therapy in heart failure patients: a meta-analysis

  2015cites this paper
• Chapitre 13 – Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diabétique

  2014cites this paper
• Acute Heart Transplant Graft Failure in Association with Hyperosmolar Hyperglycemia State

  2014cites this paper
• Gene and Gene-Set Analysis for Genome-Wide Association Studies

  2013influential citation
• Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes.

  2013cites this paper
• Evaluating the potential benefits of metformin in patients with cardiovascular disease and heart failure.

  2013cites this paper
• Primary Prevention of Heart Failure

  2012cites this paper
• Glucose and Low-Density Lipoprotein Cholesterol Lowering in Elderly Patients with Type 2 Diabetes

  2012cites this paper
• Detecting pre-diabetes and the role of the pharmacist

  2011cites this paper
• Patients with a future diagnosis of diabetes have higher drug use and costs: an analysis of community pharmacy data

  2011cites this paper
• Heart Failure Prevention

  2011cites this paper
• PROTECTIVE EFFECT OF BUTEA MONOSPERMA ON HIGH­FAT DIET AND STREPTOZOTOCIN­ INDUCED NON­GENETIC RAT MODEL OF TYPE 2 DIABETES: BIOCHEMICAL AND HISTOLOGICAL EVIDENCES

  2011cites this paper
• Characterization of cAMP-Specific Phosphodiesterase-4 (R)-[11C]Rolipram Small Animal Positron Emission Tomography and Application in a Streptozotocin-Induced Model of Hyperglycemia

  2011cites this paper
• Chapitre 12 – Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diabétique

  2010cites this paper
• Prevalence, clinical characteristics and outcome in patients with chronic heart failure and diabetes.

  2010cites this paper
• Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay

  2010cites this paper
• An intriguing association between congestive heart failure and diabetes mellitus.

  2010cites this paper
• Protective effects of mildronate in an experimental model of type 2 diabetes in Goto‐Kakizaki rats

  2009cites this paper
• A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus.

  2009cites this paper
• Recent Publications on Medications and Pharmacy

  2009cites this paper
• Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies.

  2009cites this paper
• Recent Publications on Medications and Pharmacy

  2008cites this paper
• Advanced Chronic Heart Failure and Heart Transplantation

  2008cites this paper
• Impact of diabetes and hypertension on the heart

  2008cites this paper
• Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy

  2007cites this paper
• A CROSS-SECTIONAL STUDY ON THE ASSOCIATION OF DPP-4 INHIBITORS AND PHYSIOLOGICAL RISK FACTORS OF HEART FAILURE

  year unknowncites this paper